BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Neurome: Elects Khoury, Wender To Board Of Directors


10/19/2005 5:11:46 PM

LA JOLLA, Calif., Oct. 7 /PRNewswire/ -- The Board of Directors of Neurome, Inc., a privately held biotechnology company, today announced the appointment of Michael Khoury and Joseph Wender to its Board of Directors.

Joseph Wender is an Advisory Director and Senior Director of the Financial Institutions Group at the global investment banking firm, Goldman, Sachs & Co., and Michael Khoury is a financial advisor and independent consultant. These additions bring Neurome's total Board membership to six.

Commenting on the new appointments to the Board, Floyd E. Bloom, M.D., Chairman of the Board and Founding Chief Executive Officer of Neurome, remarked, "Joe Wender and Michael Khoury, both seasoned biotech investors and experienced financial professionals, complement the strengths of our current Board. We are gratified by their expressions of confidence in Neurome and look forward to their important contributions to our evolution as a leader in discovery and development of product solutions for human neurodegenerative disease."

Michael Khoury joined Deloitte & Touche, one of the nation's leading professional services firms, in 1989 and served as Senior Manager until 1993. From 1993 to 1998 Mr. Khoury served as first President, then CEO of First National Mortgage Exchange. He was Senior Vice President at IMC Mortgage, a consumer finance company, from 1998 to 1999. In 1999 he was appointed CEO of InterScore, a consulting firm that he sold in 2000 to Ballantyne, Inc., a consulting firm focused on Enterprise Resource Planning systems, where he remained as a Senior Vice President until 2003. He holds a B.S. in Mathematics from the American University of Beirut, an MFA from New York University, and an MBA from UCLA. He is a CPA and a Fulbright Scholar.

Joseph H. Wender joined Goldman Sachs in 1971 and became a General Partner of that firm in 1982 and a Limited Partner in 1992. He has been involved in most large mergers in the banking industry over the 80's and 90's, including the BankAmerica/Nations merger, the Wells Fargo/Norwest merger, and the Chase/Chemical merger. Mr. Wender sits on the board of Isis Pharmaceuticals, First Coastal Bancshares, and Affinity Financial. He is the President of the American Center for Wine, Food & the Arts, and is a Life Director of The Chicago Joffrey Ballet as well as a Member of the Board of Directors of the Actors' Fund. Mr. Wender received his Bachelors degree from Northwestern University, his LLB from Yale Law School, and his MBA from Harvard Business School.

About Neurome

Neurome, Inc. is a discovery stage biotechnology company that seeks therapeutic solutions to human neurodegenerative diseases. The company focuses its efforts on Alzheimer's disease, Parkinson's disease, Huntington's disease, and Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's disease) -- usually fatal neurodegenerative disorders that are currently untreatable and share characteristics which make them particularly amenable to Neurome's expertise and technologies.

Since its founding in 2000, Neurome has developed and optimized proprietary technologies to reveal and quantify gene expression patterns and the resultant morphological details of brain structures in normal and pathological brains with an unprecedented level of sensitivity, specificity and resolution. Neurome's unique technologies to measure and assess neurodegenerative processes at work -- at the molecular, cellular and macroscopic levels -- are ideally suited to identify the earliest evidence of pathology in models of human diseases of the Central Nervous System, as well as to evaluate the comparative effectiveness of pharmaceutical candidates for intervention. The company dedicates these technologies to discovery and development of drugs to provide effective treatments for diseases characterized by neurodegeneration. Detailed information on the Neurome technologies and the scientific and medical challenges of human neurodegenerative disorders are available at Neurome's website: http://www.neurome.com/.

Neurome, Inc.

CONTACT: Floyd E. Bloom, M.D., Founding Chief Executive Officer ofNeurome, Inc., +1-858-677-0466



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->